Treatment of Non-Occlusive Thrombus in the Peroneal Vein

Initial Management Approach

The American College of Chest Physicians recommends initial anticoagulation with low-molecular-weight heparin (LMWH), fondaparinux, intravenous unfractionated heparin (UFH), or subcutaneous UFH for patients with severe symptoms or risk factors for extension 1, 2
For patients without severe symptoms or risk factors for extension, serial imaging of the deep veins for 2 weeks is suggested over initial anticoagulation, with anticoagulation recommended if the thrombus extends into the proximal veins 1

The American College of Chest Physicians considers severe symptoms, positive D-dimer test, extensive thrombosis, no reversible provoking factor for DVT, active cancer, history of VTE, and inpatient status as risk factors for thrombus extension 1, 3

The American College of Chest Physicians recommends 3 months of anticoagulation therapy for DVT provoked by surgery or a non-surgical transient risk factor 2
For unprovoked DVT, extended therapy is considered if bleeding risk is low or moderate, with 3 months of therapy recommended if bleeding risk is high 2, 3

The American College of Chest Physicians suggests LMWH, fondaparinux, IV UFH, or SC UFH as initial treatment, and vitamin K antagonists (VKAs) or LMWH for extended treatment 1, 2
For cancer-associated thrombosis, LMWH is suggested over vitamin K antagonists 2

Regular reassessment of drug tolerance, adherence, hepatic and renal function, and bleeding risk is recommended for patients on extended anticoagulation 2
Compression stockings are considered to prevent postthrombotic syndrome 2